[1] |
Field SK. Bedaquiline for the treatment multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis, 2015, 6(4):170-184. doi:10.1177/2040622315582325.
doi: 10.1177/2040622315582325
URL
|
[2] |
World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
|
[3] |
徐彩红, 赵雁林. 从《2020年全球结核病报告》看我国结核病防治工作. 中华传染病杂志, 2021, 39(7):392-397. doi:10.3760/cma.j.cn311365-20210406-00117.
doi: 10.3760/cma.j.cn311365-20210406
|
[4] |
周文强, 张爽, 初乃惠. 耐药肺结核全口服治疗方案研究的现状和展望. 中国防痨杂志, 2021, 43(9):879-882. doi:10.3969/j.issn.1000-6621.2021.09.005.
doi: 10.3969/j.issn.1000-6621.2021.09.005
|
[5] |
World Health Organization. Repaid Communication: Key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2019.
|
[6] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10):733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.006
|
[7] |
Linh NN, Viney K, Gegia M, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. ERJ, 2021, 58:2100804. doi:10.1183/13993003.00804-2021.
doi: 10.1183/13993003.00804-2021
|
[8] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001
|
[9] |
Shringarpure KS, Isaakidis P, Sagili KD, et al. “When treatment is more challenging than the disease”: A qualitative study of MDR-TB patient retention. PLoS One, 2016, 11(3):e0150849. doi:10.1371/journal.pone.0150849.
doi: 10.1371/journal.pone.0150849
|
[10] |
Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB mana-gement of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis, 2020,92S:S15-S25. doi:10.1016/j.ijid.2020.01.042.
doi: 10.1016/j.ijid.2020.01.042
|
[11] |
Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. A retrospective study. Medicine (Baltimore), 2017, 96(28):e7482. doi:10.1097/MD.0000000000007482.
doi: 10.1097/MD.0000000000007482
URL
|
[12] |
Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis, 2019, 83:72-76. doi:10.1016/j.ijid.2019.03.036.
doi: S1201-9712(19)30165-1
pmid: 30953827
|
[13] |
World Health Organization. WHO treatment guidelines for drugresistant tuberculosis. Geneva: World Health Organization, 2016.
|
[14] |
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. Geneva: World Health Organization, 2020.
|
[15] |
Bastard M, Molfino L, Mutaquiha C, et al. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique. Clin Infect Dis, 2019, 69(10):1809-1811. doi:10.1093/cid/ciz196.
doi: 10.1093/cid/ciz196
pmid: 30901021
|
[16] |
Skrahina A, Yatskevich N, Hurevich H, et al. Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus. ERJ, 2020, 56: 1591. doi:10.1183/13993003.congress-2020.1591.
doi: 10.1183/13993003.congress-2020.1591
|
[17] |
Avaliani T, Sereda Y, Davtyan H, et al. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019—2020. Monaldi Arch Chest Dis, 2021, 91(1):1679-1685. doi:10.4081/monaldi.2021.1679.
doi: 10.4081/monaldi.2021.1679
|
[18] |
姚蓉, 陆宇. 抗结核药物早期杀菌活性研究及进展. 中国防痨杂志, 2021, 43(7): 724-728. doi:10.3969/j.issn.1000-6621.2021.07.014.
doi: 10.3969/j.issn.1000-6621.2021.07.014
|
[19] |
初乃惠, 聂文娟. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版). 中国防痨杂志, 2021, 43(9):859-866. doi:10.3969/j.issn.1000-6621.2021.09.002.
doi: 10.3969/j.issn.1000-6621.2021.09.002
|
[20] |
裴异, 高静韬, 黄云辉, 等. 含贝达喹啉方案治疗44例痰菌阳性耐多药/广泛耐药肺结核24周疗效分析. 中国防痨杂志, 2021, 43(11):1139-1145. doi:10.3969/j.issn.1000-6621.2021.11.007.
doi: 10.3969/j.issn.1000-6621.2021.11.007
|
[21] |
杨松, 严晓峰. 贝达喹啉治疗耐多药与广泛耐药结核病的现状和展望. 结核病与肺部健康杂志, 2019, 8(4):249-252. doi:10.3969/j.issn.2095-3755.2019.04.004.
doi: 10.3969/j.issn.2095-3755.2019.04.004
|
[22] |
中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018, 41(1):14-19. doi:10.3760/cma.j.issn.1001-0939.2018.01.006.
doi: 10.3760/cma.j.issn.1001-0939.2018.01.006
|
[23] |
Yoon HY, Jo KW, Nam GB, et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis, 2017, 21(9):996-1001. doi:10.5588/ijtld.17.0174.
doi: 10.5588/ijtld.17.0174
pmid: 28826448
|
[24] |
TB Alliance. New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid[EB/OL]. [2022-06-28]. https://www.tballiance.org.za/news/zenix-press-release-english.
|